New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...
Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period ...
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...
Ifetroban demonstrated significant 5.4% improvement in cardiac functionNASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharma ...
The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular ...
Clinical Trials Arena on MSN13d
Dyne’s DMD trial advances patient mobility and dystrophin expressionThe Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback